JP2015525237A5 - - Google Patents

Download PDF

Info

Publication number
JP2015525237A5
JP2015525237A5 JP2015518318A JP2015518318A JP2015525237A5 JP 2015525237 A5 JP2015525237 A5 JP 2015525237A5 JP 2015518318 A JP2015518318 A JP 2015518318A JP 2015518318 A JP2015518318 A JP 2015518318A JP 2015525237 A5 JP2015525237 A5 JP 2015525237A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
composition
seq
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015518318A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015525237A (ja
JP6087429B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2013/000983 external-priority patent/WO2013191352A1/en
Publication of JP2015525237A publication Critical patent/JP2015525237A/ja
Publication of JP2015525237A5 publication Critical patent/JP2015525237A5/ja
Application granted granted Critical
Publication of JP6087429B2 publication Critical patent/JP6087429B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015518318A 2012-06-21 2013-02-07 変形されたヒト腫瘍壊死因子受容体−1ポリペプチドの新規用途 Active JP6087429B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20120066527 2012-06-21
KR10-2012-0066527 2012-06-21
PCT/KR2013/000983 WO2013191352A1 (en) 2012-06-21 2013-02-07 New uses of modified human tumor necrosis factor receptor-1 polypeptide

Publications (3)

Publication Number Publication Date
JP2015525237A JP2015525237A (ja) 2015-09-03
JP2015525237A5 true JP2015525237A5 (enExample) 2016-04-28
JP6087429B2 JP6087429B2 (ja) 2017-03-01

Family

ID=49768924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015518318A Active JP6087429B2 (ja) 2012-06-21 2013-02-07 変形されたヒト腫瘍壊死因子受容体−1ポリペプチドの新規用途

Country Status (6)

Country Link
US (1) US9580490B2 (enExample)
JP (1) JP6087429B2 (enExample)
KR (1) KR101514238B1 (enExample)
CN (1) CN104394881B (enExample)
BR (1) BR112014031923B1 (enExample)
WO (1) WO2013191352A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107708416B (zh) * 2015-05-01 2021-06-29 Onl医疗股份有限公司 肽组合物和使用方法
CN109311976A (zh) * 2016-06-20 2019-02-05 诺华股份有限公司 使用TNFα拮抗剂治疗干眼症的方法
TWI905137B (zh) * 2021-01-14 2025-11-21 南韓商韓兀生物製藥股份有限公司 以含有天凡諾賽普特(tanfanercept)之眼用組成物治療乾眼症
US20240059767A1 (en) * 2021-01-14 2024-02-22 Hanall Biopharma Co., Ltd. Treatment of dry eye syndrome using an ophthalmic composition comprising tanfanercept
US20240059768A1 (en) * 2021-01-14 2024-02-22 Hanall Biopharma Co., Ltd. A stable ophthalmic composition comprising tanfanercept, which is free of stabilizer or substantially free of stabilizer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1521000A (en) 1998-11-06 2000-05-29 Schepens Eye Research Institute, Inc., The Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye
US6379666B1 (en) 1999-02-24 2002-04-30 Edward L. Tobinick TNF inhibitors for the treatment of neurological, retinal and muscular disorders
US6177077B1 (en) 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US6204270B1 (en) 1999-11-12 2001-03-20 Eyal S. Ron Ophthalmic and mucosal preparations
PL218992B1 (pl) 2002-07-19 2015-02-27 Abbott Biotech Ltd Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ
US20090098136A1 (en) 2007-10-15 2009-04-16 Alcon Research, Ltd. Use of tnf receptor antagonists for treating dry eye
CN101591388A (zh) * 2008-05-30 2009-12-02 上海复旦张江生物医药股份有限公司 一种可溶性tnf受体突变体
WO2011049350A2 (ko) * 2009-10-19 2011-04-28 한올바이오파마주식회사 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법
KR101273893B1 (ko) 2010-09-13 2013-06-14 한올바이오파마주식회사 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법
DK2657252T3 (en) 2010-12-23 2017-05-08 Hanall Biopharma Co Ltd MODIFIED HUMAN TUMOR CANCER FACTOR RECEPTOR-1 POLYPEPTIDE OR FRAGMENT THEREOF AND METHOD OF PRODUCING THEREOF

Similar Documents

Publication Publication Date Title
Wang et al. Anti-inflammatory role of fetuin-A in injury and infection
IL274200B1 (en) Methods, compositions, and implantable elements comprising active cells
WO2011123830A3 (en) Alpha 1-antitrypsin compositions and methods of making and using same
WO2019035880A8 (en) EXOSOMES OF PURIFIED MESENCHYMAL STEM CELLS AND USES THEREOF
JP2012115277A5 (enExample)
EA201890220A1 (ru) Вакцина против rsv
MX2024010190A (es) Inclusion del exon2 inducida por antisentido en alfa-glucosidasa acida.
BRPI1010880A2 (pt) polipeptídeos de hormônio de crescimento e métodos de fazer e usar os mesmos.
PE20240015A1 (es) Proteinas de fusion gdf15 y usos de estas
WO2013151672A3 (en) Modified polynucleotides for the production of oncology-related proteins and peptides
EA201101553A1 (ru) Полипептид, деградирующий углеводы, и его применения
RU2011140057A (ru) Способ профилактики и лечения повышенной проницаемости
WO2014202622A3 (en) Rasamsonia gene and use thereof
JP2017532343A5 (enExample)
US20160333074A1 (en) Novel polypeptide and uses thereof
PE20150923A1 (es) Moleculas de union il-17a novedosas y usos medicos de las mismas
EA201170917A1 (ru) Ген, кодирующий мутантную глюкокиназу человека, кодируемый им фермент, рекомбинантные векторы и хозяева, фармацевтические композиции и их применения, способы лечения и предупреждения болезней
DE602007014210D1 (de) Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen
JPWO2019156137A5 (enExample)
Ma et al. Identification, expression and activity analyses of five novel duck beta-defensins
JP2015533791A5 (enExample)
RU2016108808A (ru) Терапевтическое применение vegf-c и ccbe1
JP2016513471A5 (enExample)
EP2465935A3 (en) Recombinant human interferon-like proteins
PE20210918A1 (es) Composiciones y metodos para el tratamiento de la distrofia macular